Results 121 to 130 of about 754,020 (340)

Downregulation of sST2, a decoy receptor for interleukin‐33, enhances subcutaneous tumor growth in murine pancreatic cancer cells

open access: yesFEBS Open Bio, EarlyView.
Subcutaneous implantation of murine Panc02 pancreatic cancer cells depleted of sST2, a soluble decoy receptor for the proinflammatory interleukin‐33 (IL‐33), leads to a decreased number of GLUT4‐positive cancer‐associated adipocytes, reduced levels of the anti‐inflammatory molecule adiponectin, increased phosphorylation of IκBα, elevated Cxcl3 ...
Miho Akimoto   +5 more
wiley   +1 more source

Ontogeny of Ia and IgD on IgM-bearing B lymphocytes in mice. [PDF]

open access: bronze, 1977
John F. Kearney   +5 more
openalex   +1 more source

Key role for inhibins in effective T cell activation, migration and Th17 differentiation

open access: yesFEBS Open Bio, EarlyView.
Activins/inhibins modulate immune responses. Here, we show that inhibins can be produced very early after T cell activation and can act in an autocrine way, favoring Th1 versus Th17 differentiation and CCL19/CCL21 mediated migration. Recombinant inhibin A can restore the Th1/Th17 balance, highlighting the role of inhibins as key regulators of T cell ...
Sandra Ortega‐Francisco   +5 more
wiley   +1 more source

Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy

open access: yesImmunological Medicine
Our aim is to determine the number of leukocytes, T lymphocytes and B lymphocytes and the expression of activation markers CD200 and CD23 on B lymphocytes in atopic dermatitis (AD) patients (treated and not treated with dupilumab) during the pollen ...
Jarmila Čelakovská   +4 more
doaj   +1 more source

A unified model for Duchenne muscular dystrophy gene involvement in cancer: context‐dependent tumour suppression and oncogenicity

open access: yesFEBS Open Bio, EarlyView.
We propose a context‐dependent model where the Duchenne muscular dystrophy (DMD) gene acts as a tumour suppressor in aggressive tumours and as an oncogene in less aggressive ones. We propose this model as a unified framework to explain the opposing survival associations with DMD expression and to guide experimental exploration of the dual role of DMD ...
Lee Machado   +4 more
wiley   +1 more source

T and B lymphocyte antigen-positive null cell leukemias [PDF]

open access: bronze, 1977
Joseph Kaplan   +2 more
openalex   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

open access: yesFEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior   +5 more
wiley   +1 more source

The Immune System [PDF]

open access: yes, 1995
Modern biotherapy has been in use for some 30 years. The first types of biotherapy were nonspecific stimulators of the immune response, but advances in genetic engineering are allowing the mass production of pure biological products which are now being ...
Gallucci, Betty Bierut   +1 more
core   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

open access: yesFEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy